SCHEMBL3569669

SCHEMBL3569669

Cc1cc(-c2ccc(Cl)cc2Cl)nc(-c2ccnc(-c3ccc(S(=O)(=O)NC(C)(C)C)s3)c2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
MAPT P10636 4/20 0.37
RAB9A P51151 2/20 0.37
GABRA1 P14867 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ROS1 P08922 1/20 0.36
TP53 P04637 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPC1 O15118 1/20 0.34
PRNP P04156 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
HSD11B1 P28845 1/20 0.33
CCNT1 O60563 1/20 0.33
CDK9 P50750 1/20 0.33
PIK3C3 Q8NEB9 2/20 0.33
PFKFB4 Q16877 2/20 0.33
PFKFB3 Q16875 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3562453 0.89 GABRA1 (0.41) MAPTRAB9AGABRA1L3MBTL1TP53
SCHEMBL3559064 0.85 ABL1 (0.39) MAPTGABRA1PRNPRXFP1PIK3C3
SCHEMBL3565393 0.79 PFKFB4 (0.41) PFKFB4PFKFB3
SCHEMBL2403917 0.79 RXFP1 (0.35) RXFP1KDM4EPKMPIK3CG
SCHEMBL3559682 0.78 KDM4E (0.40) MAPTGABRA1TP53SMN1; SMN2RXFP1
SCHEMBL3556174 0.78 PFKFB4 (0.41) MAPTGABRA1TP53PFKFB4PFKFB3
SCHEMBL3556405 0.76 PTGS2 (0.36) MAPTGABRA1TP53KMT2ASMN1; SMN2
SCHEMBL3560038 0.75 ABL1 (0.37) GABRA1TP53KMT2ASMN1; SMN2RXFP1
SCHEMBL3557143 0.74 PFKFB4 (0.41) MAPTRAB9AKMT2APRNPRXFP1
SCHEMBL3570689 0.74 CA12 (0.41) MAPTRAB9AGABRA1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
EP-2001849-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed
WO-2007110337-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 HSP90AA1 4441/4885HSP90AB1 3776/4885MAPT 658/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 HSP90AA1 3924/4885HSP90AB1 3509/4885MAPT 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.